Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Pfizer (PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American ...

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical ...

Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and ...

Pfizer (NYSE:PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer. The study ...

BEACON CRC also included another three drug arm – Braftovi, Erbitux, and MEK inhibitor Mektovi (binimetinib) from Array Biopharma (now part of Pfizer). That wasn’t able to improve survival any ...

As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they ...

and a combination regimen for BRAF V600E-positive colorectal cancer with Pfizer’s Braftovi (encorafenib) and Eli Lilly’s Erbitux (cetuximab). It also covers Novartis’ Mekinist (trametinib ...